Opendata, web and dolomites

IPUD

IPUD – An Implantable Peritoneal Ultrafiltration Device that actively and continuously prevents fluid overload in diuretic resistant heart failure patients.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IPUD project word cloud

Explore the words cloud of the IPUD project. It provides you a very rough idea of what is the project "IPUD" about.

poised    life    solutions    charging    inomec    annually    germany    absorbs    prevent    chronic    applies    global    market    membrane    world    hydrostatic    device    fluids    israel    million    gold    sensirion    wireless    switzerland    resistant    almost    overloaded    combined    manufacturing    standard    grow    disease    kidney    therapy    time    drains    service    diuresis    17    billion    ultrafiltration    improves    weekly    preventing       minimally    team    clinical    laparoscopic    recurrence    ipud    hospitals    peritoneal    treatment    24    invasive    approximately    education    academic    complications    secured    intraperitoneal       decade    diuretics    dialysis    interfaces    clinics    recharging    extracellular    systemic    cardiology    made    classic    congestion    acute    gradient    congestive    worth    subcontractors    bossert    senior    distributors    full    heart    cagr    hf    distress    diuretic    flat    recurred    removing    kast    isotonic    treatments    sold    carry    sectors    slowly    medical    basis    projected    overload    symptom    fluid    independently    kidneys    pressure    26    function    collaborations    urinary    headcount    2025    absorption    accumulation    aggressively    implantable    extensive    raised    ckd    patients    staff   

Project "IPUD" data sheet

The following table provides information about the project.

Coordinator
PARAGATE MEDICAL LTD 

Organization address
address: 13 WADI EL HADJ
city: NAZARETH
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website http://paragate-medical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2018-11-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PARAGATE MEDICAL LTD IL (NAZARETH) coordinator 50˙000.00

Map

 Project objective

Fluid overload (congestion) is a classic clinical symptom and cause of distress among heart failure (HF) and chronic kidney disease (CKD) patients. Diuretics are currently the gold standard treatment but of the 26 million heart failure patients annually around the world, over one third are diuretic resistant. Current solutions for fluid overload in diuretic resistant patients such as IV diuresis, ultrafiltration therapy and peritoneal dialysis all carry complications and are acute treatments which do not prevent recurrence.

IPUD improves the clinical condition of fluid overloaded patients by continuously removing extracellular fluids with a unique implantable peritoneal ultrafiltration device, operating non-aggressively and independently from the kidneys’ function. IPUD is minimally invasive (laparoscopic approach) and the flat absorption device interfaces with the intraperitoneal membrane and applies a hydrostatic pressure gradient. It then continuously (24/7) and slowly absorbs systemic isotonic extracellular fluid and drains it to the urinary system preventing recurred accumulation. The device has a projected service life of 3 years and recharging the device has been made simple for the patients via wireless charging, needed on a weekly basis.

The global congestive heart failure treatment device market is worth almost $6 billion and is poised to grow at a CAGR of around 6.4% over the next decade to reach approximately $17.8 billion by 2025. IPUD will be sold directly to hospitals and clinics for approximately €30,000 through collaborations with the major distributors of heart failure devices.

Our senior team has over 50 years’ experience in the cardiology and medical device sectors combined with extensive academic education. We have raised €1 million in funding. Our full-time staff headcount is 4. Partnerships have been secured with several manufacturing subcontractors, including Sensirion in Switzerland, Inomec in Israel and Bossert Kast in Germany.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPUD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPUD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

TuneFork (2018)

Mobile technology that brings personalized audio into your life

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More